BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 05, 2007
 |  BioCentury  |  Product Development

Targeting obesity subgroups

Both of the obesity therapeutics Orexigen Therapeutics Inc. is developing are oral, twice-daily combinations of approved drugs that include extended-release bupropion as one of their components. But the second component of each gives the two therapies different mechanisms of action that the company believes will be suited for different patient populations.

OREX presented full data from its Phase IIb trial of Empatic at the recent North American Association for the Study of Obesity (NAASO) meeting in New Orleans, as well as preclinical data on the mechanism of its more advanced compound, Contrave.

Bupropion is an off-patent dual dopamine and norepinephrine reuptake inhibitor marketed by GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) as Wellbutrin to treat depression and as Zyban for smoking cessation.

According to OREX (San Diego, Calif.), bupropion stimulates proopiomelanocortin (POMC) neurons in the hypothalamus to release alpha melanocyte-stimulating...

Read the full 715 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >